Searched for
CRDMO SERVICES INDIA
“Reallocate, Diversify, Reposition”: Ajay Srivastava flags rising macro risks for investorsIndian markets face rising macro risks from global shocks, currency pressure, and energy prices, impacting domestic consumption and corpora...- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- Anthem BioSciences shares jump 4% as Citi initiates with Buy rating. Check target, upside potentialShares of Anthem BioSciences rose after Citi initiated coverage with a Buy rating and a target price of ₹870, implying over 20% upside. Ana...
- Nomura initiates coverage on this recently-listed CRDMO stock, sees 18% upside despite 22% correctionNomura has initiated coverage on Anthem Biosciences with a Buy rating and a ₹740 target, citing attractive valuations, strong CRDMO positio...
- ETMarkets Smart Talk| Aditya Sood sees multi-year upside in financials and domestic manufacturing themesAditya Sood of InCred Asset Management is bullish on India's market, expecting financials and domestic manufacturing to lead wealth creatio...
- Cohance Lifesciences and other pharma stocks jump up to 5% after Jefferies initiates Buy recommendationCohance Lifesciences, Divi’s Laboratories, and SAI Life Sciences rallied after Jefferies initiated coverage with ‘Buy’ ratings, citing stro...
- Avendus Fund, SBI Life lead funding in AragenAvendus Future Leaders Fund and SBI Life Insurance have collectively invested ₹300 crore in Aragen Life Sciences, acquiring a 2.5% stake in...
- Trump tariff assault hits over 40 Indian stocks. Full list across key sectors for stock market investorsIndian markets initially stumbled but recovered following Trump's tariff announcement, with export-heavy sectors like textiles, pharma, and...
- Anthem Biosciences IPO: Rs 3,395 crore IPO to open on July 14Anthem Biosciences' Rs 3,395 crore IPO will open on July 14 as a complete Offer for Sale by promoters and investors. The Bengaluru-based CR...
- India's CRDMO sector can touch USD 25 bn in size by 2035: ReportIndia's CRDMO sector has the potential to reach USD 22-25 billion by 2035, driven by supply chain de-risking, pricing pressures, and demand...
- India becoming an attractive option for global pharmaceutical supply chain: Macquarie ReportIndia's CRDMO industry is projected to grow from USD 7 billion to USD 14 billion by 2028, driven by pharmaceutical outsourcing and regulato...
- Anthem Biosciences files DRHP for Rs 3,395 crore IPOAnthem Biosciences, a CRDMO, has filed for a Rs 3,395 crore IPO. The offer comprises an OFS by promoters and investors, including True Nort...
- Anthem Biosciences files DRHP for Rs 3,395 crore IPOAnthem Biosciences has filed its DRHP for an IPO. The issue comprises an offer for sale of up to Rs 3,395 crore by promoters and investors....
- Buy Piramal Pharma, target price Rs 340: JM FinancialJM Financial recommends buying Piramal Pharma stock. The target price is Rs 340. The current market price is Rs 260.55. India's CRDMO indus...
- Quadria Capital to pick up minority stake in drug company AragenQuadria Capital is set to acquire a 10% stake in Aragen Life Sciences for about $100 million, valuing the Indian CRDMO at $1.2 billion. The...
- Sai Life Sciences IPO subscribed 1.25 times on Day 2. Check key dates, price band, GMP, and reviewSai Life Sciences IPO: Sai Life Sciences' IPO saw full subscription on its second day, with a 1.25 times oversubscription. Retail investors...
- Sai Life Sciences IPO Day 1: Issue subscribed 84% led by QIBs. Check GMP, other key detailsThe IPO of the contract research and manufacturing firm opened for subscription on Wednesday, achieving 84% overall subscription on the fir...
- Sai Life Science grew fast, but pricing looks expensiveThe issue gives a partial exit to private equity investors TPG Asia and HBM. The promoter share will be diluted from 41.8% to 35.2%. The is...
- Sai Life Sciences IPO opens tomorrow. Check latest GMP, price band, key datesSai Life Sciences' unlisted shares traded at Rs 577 on Tuesday in the grey market, indicating a 5.1% premium over the IPO price band’s uppe...
- India could account for 8-10 pc of work share outsourced to CDMOs by 2033: ReportIndia could take 8-10% of the global outsourcing share for Contract Research Development and Manufacturing Organisations by 2033 due to wor...
Load More
